Shield Therapeutics (LON:STX) Hits New 12-Month High – Still a Buy?

Shares of Shield Therapeutics plc (LON:STX) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as GBX 12.50 and last traded at GBX 11.50, with a volume of 2757713 shares traded. The stock had previously closed at GBX 11.20.

Analysts Set New Price Targets

Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a report on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of GBX 15.

Shield Therapeutics Price Performance

The firm has a market capitalization of £122.11 million, a price-to-earnings ratio of -5.75 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The stock’s 50 day moving average price is GBX 8.18 and its two-hundred day moving average price is GBX 6.21.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.